BackgroundNon‐invasive evaluation of phosphomonoesters (PMEs) and phosphodiesters (PDEs) by 31‐phosphorus MR spectroscopy (31P MRS) may have potential for early therapy (non‐)response assessment in cancer. However, 31P MRS has not yet been applied to investigate the human pancreas in vivo.PurposeTo assess the technical feasibility and repeatability of 31P MR spectroscopic imaging (MRSI) of the pancreas, compare 31P metabolite levels between pancreas and liver, and determine the feasibility of 31P MRSI in pancreatic cancer.Study TypeProspective cohort study.Population10 healthy subjects (age 34 ± 12 years, four females) and one patient (73‐year‐old female) with pancreatic ductal adenocarcinoma.Field Strength/Sequence7‐T, 31P FID‐MRSI, 1H gradient‐echo MRI.Assessment31P FID‐MRSI of the abdomen (including the pancreas and liver) was performed with a nominal voxel size of 20 mm (isotropic). For repeatability measurements, healthy subjects were scanned twice on the same day. The patient was only scanned once. Test–retest 31P MRSI data of pancreas and liver voxels (segmented on 1H MRI) of healthy subjects were quantified by fitting in the time domain and signal amplitudes were normalized to γ‐adenosine triphosphate. In addition, the PME/PDE ratio was calculated. Metabolite levels were averaged over all voxels within the pancreas, right liver lobe and left liver lobe, respectively.Statistical TestsRepeatability of test–retest data from healthy pancreas was assessed by paired t‐tests, Bland–Altman analyses, and calculation of the intrasubject coefficients of variation (CoVs). Significant differences between healthy pancreas and right and left liver lobes were assessed with a two‐way analysis of variance (ANOVA) for repeated measures. A P‐value <0.05 was considered statistically significant.ResultsThe intrasubject CoVs for PME, PDE, and PME/PDE in healthy pancreas were below 20%. Furthermore, PME and PME/PDE were significantly higher in pancreas compared to liver. In the patient with pancreatic cancer, qualitatively, elevated relative PME signals were observed in comparison with healthy pancreas.Data ConclusionIn vivo 31P MRSI of the human healthy pancreas and in pancreatic cancer may be feasible at 7 T.Evidence Level3Technical EfficacyStage 2

中文翻译：

---

胰腺中的 31P 磁共振波谱：可重复性、与肝脏的比较以及胰腺癌试点数据

背景通过 31 磷 MR 光谱对磷酸单酯 (PME) 和磷酸二酯 (PDE) 进行非侵入性评估（31P MRS）可能具有用于癌症早期治疗（无）反应评估的潜力。然而，31P MRS 尚未应用于研究人类胰腺体内.目的评估技术可行性和可重复性31胰腺 P MR 光谱成像 (MRSI)，比较31胰腺和肝脏之间的 P 代谢水平，并确定可行性31胰腺癌中的 P MRSI。研究类型前瞻性队列研究。人群 10 名健康受试者（年龄 34 ± 12 岁，四名女性）和一名胰腺导管腺癌患者（73 岁女性）。场强/序列7-T，31P FID-MRSI，1H梯度回波MRI评估31腹部（包括胰腺和肝脏）的 P FID-MRSI 的标称体素大小为 20 毫米（各向同性）。为了进行可重复性测量，健康受试者在同一天被扫描两次。患者只接受了一次扫描。测试-再测试31P 胰腺和肝脏体素的 MRSI 数据（分段1通过时域拟合对健康受试者的 H MRI）进行量化，并将信号幅度标准化为 γ-三磷酸腺苷。此外，还计算了PME/PDE比率。代谢水平分别对胰腺、右肝叶和左肝叶内的所有体素进行平均。统计测试健康胰腺的重测数据的可重复性通过配对评估t‐测试、Bland-Altman 分析以及受试者内变异系数 (CoV) 的计算。通过重复测量的双向方差分析（ANOVA）评估健康胰腺与左右肝叶之间的显着差异。A磷‐值<0.05被认为具有统计学意义。结果健康胰腺中PME、PDE和PME/PDE的受试者内冠状病毒低于20%。此外，与肝脏相比，胰腺中的 PME 和 PME/PDE 显着更高。在胰腺癌患者中，与健康胰腺相比，定性地观察到相对 PME 信号升高。 数据结论体内 31人类健康胰腺和胰腺癌的 P MRSI 在 7 T 时可能是可行的。证据级别 3 技术功效阶段 2